While it continues to deny all kickback allegations raised in a whistleblower suit filed seven years ago, Biogen Inc. agreed Sept. 26 to pay $900 million to resolve claims that it paid doctors in the U.S. to prescribe its multiple sclerosis drugs from 2009 through March 2014.

Read Full Story: https://www.bioworld.com/articles/690034-biogen-to-pay-900m-to-end-whistleblo...